tbuckley/cabot-search huggingface dataset:
集学的なアプローチにより原発性糸球体腎症を評価するネフローゼ症候群研究ネットワーク(NEPTUNE)の設計 | 文献情報 | J-GLOBAL 科学技術総合リンクセンター
Authors: A Gadegbeku Crystal, S Gipson Debbie, B Holzman Lawrence, O Ojo Akinlolu, X K Song Peter, Barisoni Laura, G Sampson Matthew, B Kopp Jeffrey, V Lemley Kevin, J Nelson Peter, C Lienczewski Chrysta, G Adler Sharon, B Appel Gerald, C Cattran Daniel, J Choi Michael, Contreras Gabriel, M Dell Katherine, C Fervenza Fernando, L Gibson Keisha, A Greenbaum Larry, D Hernandez Joel, M Hewitt Stephen, R Hingorani Sangeeta, Hladunewich Michelle, C Hogan Marie, L Hogan Susan, J Kaskel Frederick, C Lieske John, E C Meyers Kevin, H Nachman Patrick, C Nast Cynthia, M Neu Alicia, N Reich Heather, R Sedor John, B Sethna Christine, Trachtman Howard, R Tuttle Katherine, Zhdanova Olga, E Zilleruelo Gaston, Kretzler Matthias
Journal: Kidney International (2013)
Evidence of SARS-CoV-2 mRNA in endomyocardial biopsies of patients with clinically suspected myocarditis tested negative for COVID-19 in nasopharyngeal swab
Authors: Philip Wenzel, Sabrina Kopp, Sebastian Göbel, Thomas Jansen, Martin Geyer, Felix Hahn, Karl-Friedrich Kreitner, Felicitas Escher, Heinz-Peter Schultheiss, Thomas Münzel
Journal: Cardiovascular Research (2020)
Institutionalisation and deinstitutionalisation of children 1: a systematic and integrative review of evidence regarding effects on development
Authors: Marinus H van IJzendoorn, Marian J Bakermans-Kranenburg, Robbie Duschinsky, Nathan A Fox, Philip S Goldman, Megan R Gunnar, Dana E Johnson, Charles A Nelson, Sophie Reijman, Guy C M Skinner, Charles H Zeanah, Edmund J S Sonuga-Barke
Journal: The Lancet Psychiatry (2020)
Abstraction still holds its feet on the ground
Authors: Mariella Pazzaglia, Erik Leemhuis
Journal: Behavioral and Brain Sciences (2020)

Abstract In view of current scientific knowledge, it seems premature to hypothesize a qualitative distinction between processes, networks, and structures involved in abstract processes from those based on perception, episodic, or procedural memories. Predictive thought and mental travel strongly rely, at different levels of consciousness, on past and ongoing sensory input, bodily information (e.g., interoception), and the results of perceptual elaboration.
Soma-Targeted Imaging of Neural Circuits by Ribosome Tethering
Authors: Yiming Chen, Heeun Jang, Perry W.E. Spratt, Seher Kosar, David E. Taylor, Rachel A. Essner, Ling Bai, David E. Leib, Tzu-Wei Kuo, Yen-Chu Lin, Mili Patel, Aygul Subkhangulova, Saul Kato, Evan H. Feinberg, Kevin J. Bender, Zachary A. Knight, Jennifer L. Garrison
Journal: Neuron (2020)
心疾患:Ca 2+ 緩衝を遅延させることをねらって設計された非典型的EFハンドモチーフは心機能を増強する
Authors: Wang Wang, Barnabei Matthew S, Asp Michelle L, Heinis Frazer I, Arden Erik, Davis Jennifer, Metzger Joseph M, Braunlin Elizabeth, Li Qi, Potter James D, Davis Jonathan P
Journal: Nature Medicine (2013)
Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020
Authors: Elena Percivalle, Giuseppe Cambiè, Irene Cassaniti, Edoardo Vecchio Nepita, Roberta Maserati, Alessandro Ferrari, Raffaella Di Martino, Paola Isernia, Francesco Mojoli, Raffaele Bruno, Marcello Tirani, Danilo Cereda, Carlo Nicora, Massimo Lombardo, Fausto Baldanti
Journal: Eurosurveillance (2020)

We evaluated SARS-CoV-2 RNA and neutralising antibodies in blood donors (BD) residing in the Lodi Red Zone, Italy. Of 390 BDs recruited after 20 February 2020 − when the first COVID-19 case in Lombardy was identified, 91 (23%) aged 19–70 years were antibody positive. Viral RNA was detected in an additional 17 (4.3%) BDs, yielding ca 28% (108/390) with evidence of virus exposure. Five stored samples collected as early as 12 February were seropositive.
Abstract 16266: Residual Mitral Regurgitation After Aortic Valve Replacement in Patients With Severe Aortic Stenosis: Echocardiographic Predictors and Impact on Long-Term Survival
Authors: Emile Voisine, Pierre Voisine, Frédéric Beaupré, Mohamed Marzouk, Mario Sénéchal
Journal: Circulation (2019)

Background: Whether patients with severe aortic stenosis (AS) and significant mitral regurgitation (MR) should undergo isolated aortic (AVR) or double aortic and mitral valve replacement (DVR) rema...
Transparent nanoliter container supports cell delivery and imaging of post-transplant cell function
Authors: Barjor Gimi, Joonbum Kwon, Jeong-Bong Lee, Paul Winnard, Venu Raman, Zaver Bhujwalla
Journal: Cancer Research (2008)

5139  We have devised optically-transparent microcontainers for cell encapsulation and to visualize cell viability and function post-transplantation - these biocompatible microcontainers were used to deliver tumor cells and can be used as a delivery vehicle in cell based anti-tumor therapy.  We fabricated hollow cubic microcontainers from a transparent epoxy-based polymer, with an 8 nl encapsulation volume. We encapsulated 1000 red-fluorescent protein-expressing MDA-MB-231-tdTomato cancer cells within each microcontainer and implanted the microcontainers in the mammary fat pads of SCID mice. The tumor burden was observed up to 20 days post-implantation, followed by excision of the implant site. A microcontainer with no cells served as a control.  Fluorescence imaging revealed the encapsulated cells immediately post-implantation; there was no autofluorescence from the control microcontainer. Cancer cells embedded in these microcontainers remained viable for more than 20 days. One mouse was euthanized after 16 days and the microcontainer with cells was excised. Cells from the excised microcontainer revealed viable cells that formed cell colonies in culture. For microcontainers that were not retrieved, the cells grew into tumors.  The results demonstrate that we can sequester a precise and small number of cells for localized delivery. These cells are easily visible in the transparent microcontainers, post implantation. The cell-encapsulating microcontainers supported cell survival; no deleterious effects to the encapsulated cells or to the host were observed. The microcontainers can potentially serve as a vehicle for cells that secrete therapeutic molecules, for stem cells used in regeneration, or to deliver cancer cells as inocula. In encapsulating cellular xenografts, that require immunoprotection, the microcontainers can be rendered nanoporous to exclude macrophages and large immune molecules from their interior. Our approach can be easily modified to fabricate a wide range of microcontainer sizes, thereby providing the ability to encapsulate single cells or large cellular clusters and allow access to different regions within the body.  Our microcontainers provide a means of placing cells overexpressing specific chemokines or cytokines under optical or MRI image-guidance in microenvironment specific e.g. hypoxic versus normoxic regions of the tumor.  Acknowledgement: We gratefully acknowledge funding from NIH/NIBIB 1R01 EB007456-01.
Abstract IA05: ctDNA and MRD in colorectal cancer: Time to reinvent adjuvant clinical trials
Authors: Jeanne Tie, Nickolas Papadopoulos, Kenneth Kinzler, Bert Vogelstein, Peter Gibbs
Journal: Clinical Cancer Research (2020)

Abstract The most substantial opportunity for improving cancer survival outcomes is in the setting of early-stage disease, where evidence indicates that adjuvant chemotherapy can reduce recurrence and prevent cancer-related death through the eradication of minimal residual disease. However, the current stage-based treatment approach lacks precision and has quite a modest survival impact. A powerful prognostic marker could revolutionize adjuvant therapy by (i) better defining the recurrence risk of individual patients and allowing delivery of a more personalized treatment approach and (ii) enriching studies of new therapies with high-risk patients, substantially reducing the size and cost of adjuvant therapy trials. Circulating tumor DNA (ctDNA) has emerged as a promising noninvasive biomarker, with the ability to detect minimal residual disease following curative intent treatment in early-stage colorectal cancer. I will discuss the potential clinical utilities of ctDNA in early-stage colorectal cancer, including ongoing biomarker-driven adjuvant randomized trials. Citation Format: Jeanne Tie, Nickolas Papadopoulos, Kenneth Kinzler, Bert Vogelstein, Peter Gibbs. ctDNA and MRD in colorectal cancer: Time to reinvent adjuvant clinical trials [abstract]. In: Proceedings of the AACR Special Conference on Advances in Liquid Biopsies; Jan 13-16, 2020; Miami, FL. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(11_Suppl):Abstract nr IA05.
Prehabilitation vs Postoperative Rehabilitation for Frail Patients
Authors: Francesco Carli, Guillaume Bousquet-Dion, Julio F. Fiore
Journal: JAMA Surgery (2020)

In Reply We appreciate the opportunity to reply to the comments regarding our article1 on prehabilitation for frail patients undergoing colorectal cancer resection. These comments reflect a growing and enthusiastic interest in improving the quality of surgical care using prehabilitation.
Implications for Design and Analyses of Oncology Clinical Trials During the COVID-19 Pandemic
Authors: Chaya S. Moskowitz, Katherine S. Panageas
Journal: JAMA Oncology (2020)

mation on alternative therapies.Shared decision-making needs to be a component of our standards.Finally, we need to address and eliminate inequities in care.Health care is migrating from a fee-for-service model to a value-based or shared-risk model of reimbursement; our metrics and incentives should also be value based.It is time for standards of cancer care to include patient experience and cost in addition to traditional quality metrics.Societies that have a stake in breast cancer care have an opportunity to partner with each other and with patients to create holistic value-based guidelines that, if embraced, will further improve cancer care.The American College of Surgeons' quality and cancer programs are currently developing value-based metrics.The NAPBC has representation from all disciplines, including patient advocacy groups, and is well suited to lead this effort.There is no need to wait for a cure for many patients with breast cancer at our institutions.We have the cure, if we work together with those we serve.
Association of Sedentary Behavior With Cancer Mortality in Middle-aged and Older US Adults
Authors: Susan C. Gilchrist, Virginia J. Howard, Tomi Akinyemiju, Suzanne E. Judd, Mary Cushman, Steven P. Hooker, Keith M. Diaz
Journal: JAMA Oncology (2020)

Sedentary behavior is associated with several health outcomes, including diabetes, cardiovascular disease, and all-cause mortality. Less is known about the association between objectively measured sedentary behavior and cancer mortality, as well as the association with physical activity.To examine the association between accelerometer-measured sedentary behavior (total volume and accrual in prolonged, uninterrupted bouts) and cancer mortality.A prospective cohort study conducted in the contiguous US included 8002 black and white adults aged 45 years or older enrolled in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study. The present analysis was performed from April 18, 2019, to April 21, 2020.Sedentary time, light-intensity physical activity (LIPA), and moderate- to vigorous-intensity physical activity (MVPA) were measured using a hip-mounted accelerometer worn for 7 consecutive days.Cancer mortality.Of the 8002 study participants, 3668 were men (45.8%); mean (SD) age was 69.8 (8.5) years. Over a mean (SD) follow-up of 5.3 (1.5) years, 268 participants (3.3%) died of cancer. In multivariable-adjusted models, including MVPA, greater total sedentary time was associated with a greater risk of cancer mortality (tertile 2 vs tertile 1: hazard ratio [HR], 1.45; 95% CI, 1.00-2.11; tertile 3 vs tertile 1: HR, 1.52; 95% CI, 1.01-2.27). Longer sedentary bout duration was not significantly associated with greater cancer mortality risk: after adjustment for MVPA (tertile 2 vs tertile 1: HR, 1.26; 95% CI, 0.90-1.78; tertile 3 vs tertile 1: HR, 1.36; 95% CI, 0.96-1.93). Replacing 30 minutes of sedentary time with LIPA was significantly associated with an 8% (per 30 minutes: HR, 0.92; 95% CI, 0.86-0.97) lower risk of cancer mortality; MVPA was significantly associated with a 31% (per 30 minutes: HR, 0.69; 95% CI, 0.48-0.97) lower risk of cancer mortality.In this cohort study, greater sedentary time, as measured with accelerometry, appeared to be independently associated with cancer mortality risk. Replacing sedentary time with either LIPA or MVPA may be associated with a lower risk of cancer mortality. These findings suggest that the total volume of sedentary behavior is a potential cancer mortality risk factor and support the public health message that adults should sit less and move more to promote longevity.
Tumor growth rate constants derived from data gathered while patients are on clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data
Authors: wilfred stein, Susan Bates, William Figg, William Dahut, Tito Fojo
Journal: Cancer Research (2007)

2662  We present a new method for analyzing the changes in tumor measurements in patients enrolled in clinical trials. Using tumor measurement data obtained in patients with renal cell cancer enrolled on a clinical trial with the novel epothilone B analogue, BMS 247550 (Ixabepilone), we curve-fitted with an equation that takes into account the rate of tumor regression (with regression rate constant e) as well as the concomitant rate of increase (with growth rate constant b). We showed mathematically that the minimum value (nadir) and the time to nadir can be viewed as surrogates for the underlying kinetic parameters of regression rate and growth rate since both are determined by e and b. To confirm that the equation could fit data from patients with other malignancies, we evaluated serial levels of the prostate specific antigen (PSA) in 112 patients with prostate cancer. Curve-fitting, we obtained reliable measures of the growth rate constant (with p
Sex Differences in Valve-Calcification Activity and Calcification Progression in Aortic Stenosis
Authors: Frederique E.C.M. Peeters, Mhairi K. Doris, Timothy R.G. Cartlidge, Jacek Kwiecinski, Tania A. Pawade, William S.A. Jenkins, Bas L.J.H. Kietselaer, Harry J.G.M. Crijns, David E. Newby, Marc R. Dweck
Journal: JACC. Cardiovascular imaging (2020)
Systematic or Test-Guided Treatment for Tuberculosis in HIV-Infected Adults
Authors: François-Xavier Blanc, Anani D Badje, Maryline Bonnet, Delphine Gabillard, Eugène Messou, Conrad Muzoora, Sovannarith Samreth, Bang D Nguyen, Laurence Borand, Anaïs Domergue, Delphine Rapoud, Naome Natukunda, Sopheak Thai, Sylvain Juchet, Serge P Eholié, Stephen D Lawn, Serge K Domoua, Xavier Anglaret, Didier Laureillard
Journal: New England Journal of Medicine (2020)

In regions with high burdens of tuberculosis and human immunodeficiency virus (HIV), many HIV-infected adults begin antiretroviral therapy (ART) when they are already severely immunocompromised. Mortality after ART initiation is high in these patients, and tuberculosis and invasive bacterial diseases are common causes of death.We conducted a 48-week trial of empirical treatment for tuberculosis as compared with treatment guided by testing in HIV-infected adults who had not previously received ART and had CD4+ T-cell counts below 100 cells per cubic millimeter. Patients recruited in Ivory Coast, Uganda, Cambodia, and Vietnam were randomly assigned in a 1:1 ratio to undergo screening (Xpert MTB/RIF test, urinary lipoarabinomannan test, and chest radiography) to determine whether treatment for tuberculosis should be started or to receive systematic empirical treatment with rifampin, isoniazid, ethambutol, and pyrazinamide daily for 2 months, followed by rifampin and isoniazid daily for 4 months. The primary end point was a composite of death from any cause or invasive bacterial disease within 24 weeks (primary analysis) or within 48 weeks after randomization.A total of 522 patients in the systematic-treatment group and 525 in the guided-treatment group were included in the analyses. At week 24, the rate of death from any cause or invasive bacterial disease (calculated as the number of first events per 100 patient-years) was 19.4 with systematic treatment and 20.3 with guided treatment (adjusted hazard ratio, 0.95; 95% confidence interval [CI], 0.63 to 1.44). At week 48, the corresponding rates were 12.8 and 13.3 (adjusted hazard ratio, 0.97 [95% CI, 0.67 to 1.40]). At week 24, the probability of tuberculosis was lower with systematic treatment than with guided treatment (3.0% vs. 17.9%; adjusted hazard ratio, 0.15; 95% CI, 0.09 to 0.26), but the probability of grade 3 or 4 drug-related adverse events was higher with systematic treatment (17.4% vs. 7.2%; adjusted hazard ratio 2.57; 95% CI, 1.75 to 3.78). Serious adverse events were more common with systematic treatment.Among severely immunosuppressed adults with HIV infection who had not previously received ART, systematic treatment for tuberculosis was not superior to test-guided treatment in reducing the rate of death or invasive bacterial disease over 24 or 48 weeks and was associated with more grade 3 or 4 adverse events. (Funded by the Agence Nationale de Recherches sur le Sida et les Hépatites Virales; STATIS ANRS 12290 ClinicalTrials.gov number, NCT02057796.).
Circulating Proteoglycan Endocan Mediates EGFR-Driven Progression of Non–Small Cell Lung Cancer
Authors: Yi-Chieh Yang, Ke-Fan Pan, Wei-Jiunn Lee, Jer-Hwa Chang, Peng Tan, Chia-Chi Gu, Wei-Min Chang, Shun-Fa Yang, Michael Hsiao, Kuo-Tai Hua, Ming-Hsien Chien
Journal: Cancer Research (2020)

Abstract Although new generations of EGFR-tyrosine kinase inhibitors (EGFR-TKI) have been developed for the treatment of patients with non–small cell lung cancer (NSCLC) with EGFR-mutant tumors, TKI resistance often returns as a result of additional EGFR mutations. In addition to seeking for next-generation EGFR-TKI, developing novel EGFR-targeting strategies may hold the key to overcome the vicious cycle of TKI resistance. Endocan is known as a receptor tyrosine kinase ligand enhancer in tumorigenesis, but the impact of endocan on EGFR-driven NSCLC progression remains unknown. In this study, higher endocan levels were found in lung tumors compared with cancer-free tissues and correlated with poor prognosis in patients with NSCLC harboring mutant EGFR; circulating endocan levels were also significantly higher in patients with mutant EGFR. Endocan facilitated EGFR signaling via direct binding and enhancing of the EGF–EGFR interaction and supported the growth of tumors driven by mutated EGFR. Activated EGFR in turn upregulated expression of endocan via JAK/STAT3 and ERK/ELK cascades, thus forming a positive regulatory loop of endocan-EGFR signaling. On the basis of the binding region between endocan and EGFR, we designed therapeutic peptides and demonstrated promising therapeutic effects in xenografts harboring EGFR mutations including TKI-resistant T790M. Together, our findings highlight the novel interaction between endocan and EGFR and new opportunities to effectively target endocan-EGFR regulatory axis in patients with TKI-resistant NSCLC. Significance: Endocan is a novel and critical regulator of EGF/EGFR signaling and serves as an alternative target of EGFR-TKI resistance in NSCLC.
Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease
Authors: Michael C. Honigberg, Lee-Shing Chang, Darren K. McGuire, Jorge Plutzky, Vanita R. Aroda, Muthiah Vaduganathan
Journal: JAMA Cardiology (2020)

<h3>Importance</h3> Recent randomized clinical trials have demonstrated that glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce cardiovascular events in at-risk individuals with type 2 diabetes. Despite these findings, GLP-1RAs are underused in eligible patients, particularly by cardiologists. <h3>Observations</h3> To date, randomized clinical trials of albiglutide, dulaglutide, liraglutide, and injectable semaglutide have reported favorable cardiovascular outcomes. Most recently approved for clinical use, oral semaglutide has a favorable safety profile and is currently undergoing regulatory evaluation and further study for cardiovascular outcomes. Professional society guidelines now recommend GLP-1RA therapy for cardiovascular risk mitigation in patients with type 2 diabetes and established atherosclerotic cardiovascular disease (ASCVD) or multiple ASCVD risk factors, independent of glucose control or background antihyperglycemic therapy (other diabetes medications being used). Additional conditions suitable for GLP-1RA therapy include obesity and advanced chronic kidney disease (estimated glomerular filtration rate &lt;30 mL/min/1.73 m<sup>2</sup>), for which cardiovascular risk-reducing options are limited. Out-of-pocket costs and secondary advantages (eg, weight loss) may inform shared decision-making discussions regarding potential therapies. GLP-1RA therapy has a favorable safety profile. Its most common adverse effect is gastrointestinal upset, which typically wanes during the early weeks of therapy and may be mitigated by starting at the lowest dose and escalating as tolerated. Depending on baseline glycemic control, sulfonylureas and insulin may need to be decreased before GLP-1RA initiation; without concurrent use of insulin or sulfonylureas, GLP-1RAs are not associated with hypoglycemia. Multidisciplinary follow-up and collaborative care with primary care physicians and/or endocrinologists are important. <h3>Conclusions and Relevance</h3> Findings from this review suggest that GLP-1RAs are safe, are well tolerated, and improve cardiovascular outcomes, largely independent of their antihyperglycemic properties, but they remain underused by cardiologists. This review provides a practical resource for cardiologists for initiating GLP-1RAs and managing the therapy in patients with type 2 diabetes and established ASCVD or high risk for ASCVD.
Hypogammaglobulinemia in Chronic Lymphocytic Leukemia: A Predictor of Outcome?
Authors: Gianluigi Reda, Ramona Cassin, Giorgia Levati, Bruno Fattizzo, Veronica Mattiello, Diana Giannarelli, Francesco Onida, Wilma Barcellini, Agostino Cortelezzi
Journal: Blood (2017)